share_log

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder

Benzinga Real-time News ·  Jan 31, 2022 12:30

The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebrand disease (VWD) receiving on-demand therapy.

  • Vonvendi is the only recombinant von Willebrand factor (VWF) replacement therapy and the first and only treatment to reduce the frequency of bleeding episodes for severe Type 3 VWD approved by the FDA for routine prophylactic use. 
  • Related content: Benzinga's Full FDA Calendar.
  • Vonvendi is now indicated for routine prophylaxis in adults with severe Type 3 VWD receiving on-demand therapy and on-demand and perioperative bleed management in adults with VWD.
  • VWD is an inherited disorder caused by a deficiency or impaired function of VWF, one of several types of proteins in the blood that are needed for proper blood clotting.
  • Vonvendi is an infused product specifically designed to replace the body's missing or dysfunctional VWF.
  • The approval is based on a prospective, open-label, international multicenter study. 
  • The median annualized bleeding rates (ABR) for all bleeds was reduced from historical median ABR 5.0 to an on-study median ABR of 2.3, equivalent to a 54.7% reduction. 
  • Price Action: TAK shares are up 0.10% at $14.41 during the market session on the last check Monday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment